Cargando…

Impact of CD14(++)CD16(+) monocytes on plaque vulnerability in diabetic and non-diabetic patients with asymptomatic coronary artery disease: a cross-sectional study

BACKGROUND: Previously, we have reported that daily glucose fluctuations could affect coronary plaque vulnerability, but the underlying mechanisms remained unclear. This study sought to investigate the impact of CD14(++)CD16(+) monocytes on plaque vulnerability, as assessed by virtual histology intr...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshida, Naofumi, Yamamoto, Hiroyuki, Shinke, Toshiro, Otake, Hiromasa, Kuroda, Masaru, Terashita, Daisuke, Takahashi, Hachidai, Sakaguchi, Kazuhiko, Hirota, Yushi, Emoto, Takuo, Amin, Hilman Zulkifli, Mizoguchi, Taiji, Hayashi, Tomohiro, Sasaki, Naoto, Yamashita, Tomoya, Ogawa, Wataru, Hirata, Ken-ichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549371/
https://www.ncbi.nlm.nih.gov/pubmed/28789689
http://dx.doi.org/10.1186/s12933-017-0577-8
_version_ 1783255965172236288
author Yoshida, Naofumi
Yamamoto, Hiroyuki
Shinke, Toshiro
Otake, Hiromasa
Kuroda, Masaru
Terashita, Daisuke
Takahashi, Hachidai
Sakaguchi, Kazuhiko
Hirota, Yushi
Emoto, Takuo
Amin, Hilman Zulkifli
Mizoguchi, Taiji
Hayashi, Tomohiro
Sasaki, Naoto
Yamashita, Tomoya
Ogawa, Wataru
Hirata, Ken-ichi
author_facet Yoshida, Naofumi
Yamamoto, Hiroyuki
Shinke, Toshiro
Otake, Hiromasa
Kuroda, Masaru
Terashita, Daisuke
Takahashi, Hachidai
Sakaguchi, Kazuhiko
Hirota, Yushi
Emoto, Takuo
Amin, Hilman Zulkifli
Mizoguchi, Taiji
Hayashi, Tomohiro
Sasaki, Naoto
Yamashita, Tomoya
Ogawa, Wataru
Hirata, Ken-ichi
author_sort Yoshida, Naofumi
collection PubMed
description BACKGROUND: Previously, we have reported that daily glucose fluctuations could affect coronary plaque vulnerability, but the underlying mechanisms remained unclear. This study sought to investigate the impact of CD14(++)CD16(+) monocytes on plaque vulnerability, as assessed by virtual histology intravascular ultrasound (VH-IVUS), as well as their relationship to fluctuating glucose levels in patients with asymptomatic coronary artery disease (CAD). METHODS: Fifty-one patients with asymptomatic CAD, who were undergoing lipid-lowering therapy and underwent VH-IVUS evaluation for angiographically mild to moderate lesions, were enrolled in the study. Standard VH-IVUS parameters, including the percentage volume of the necrotic core (%NC) within the plaque and the presence of a virtual histology thin-cap fibroatheroma (VH-TCFA), were then evaluated. Additionally, monocyte subsets were assessed by flow cytometry, and daily glucose fluctuations were analyzed by measuring the mean amplitude of glycemic excursion (MAGE). RESULTS: Among 82 plaques from 22 diabetes mellitus (DM) patients and 29 non-DM patients, 15 VH-TCFAs were identified. CD14(++)CD16(+) monocyte counts significantly correlated with both  %NC and the presence of VH-TCFA (%NC: r = 0.339, p = 0.002; VH-TCFA: p = 0.003). Multivariate logistic regression analysis revealed that CD14(++)CD16(+) monocyte counts were independently associated with VH-TCFA (odds ratio = 1.029, p = 0.004). Furthermore, CD14(++)CD16(+) monocyte counts were significantly correlated with the MAGE score in the non-DM patients (r = 0.544, p = 0.005). CONCLUSIONS: CD14(++)CD16(+) monocyte levels are associated with coronary plaque vulnerability and can serve as a biomarker for VH-TCFA in patients with CAD undergoing lipid-lowering therapy. In patients without DM, glucose fluctuations may alter the balance of monocyte subsets. Trial registration UMIN Registry number: UMIN000021228 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12933-017-0577-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5549371
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-55493712017-08-11 Impact of CD14(++)CD16(+) monocytes on plaque vulnerability in diabetic and non-diabetic patients with asymptomatic coronary artery disease: a cross-sectional study Yoshida, Naofumi Yamamoto, Hiroyuki Shinke, Toshiro Otake, Hiromasa Kuroda, Masaru Terashita, Daisuke Takahashi, Hachidai Sakaguchi, Kazuhiko Hirota, Yushi Emoto, Takuo Amin, Hilman Zulkifli Mizoguchi, Taiji Hayashi, Tomohiro Sasaki, Naoto Yamashita, Tomoya Ogawa, Wataru Hirata, Ken-ichi Cardiovasc Diabetol Original Investigation BACKGROUND: Previously, we have reported that daily glucose fluctuations could affect coronary plaque vulnerability, but the underlying mechanisms remained unclear. This study sought to investigate the impact of CD14(++)CD16(+) monocytes on plaque vulnerability, as assessed by virtual histology intravascular ultrasound (VH-IVUS), as well as their relationship to fluctuating glucose levels in patients with asymptomatic coronary artery disease (CAD). METHODS: Fifty-one patients with asymptomatic CAD, who were undergoing lipid-lowering therapy and underwent VH-IVUS evaluation for angiographically mild to moderate lesions, were enrolled in the study. Standard VH-IVUS parameters, including the percentage volume of the necrotic core (%NC) within the plaque and the presence of a virtual histology thin-cap fibroatheroma (VH-TCFA), were then evaluated. Additionally, monocyte subsets were assessed by flow cytometry, and daily glucose fluctuations were analyzed by measuring the mean amplitude of glycemic excursion (MAGE). RESULTS: Among 82 plaques from 22 diabetes mellitus (DM) patients and 29 non-DM patients, 15 VH-TCFAs were identified. CD14(++)CD16(+) monocyte counts significantly correlated with both  %NC and the presence of VH-TCFA (%NC: r = 0.339, p = 0.002; VH-TCFA: p = 0.003). Multivariate logistic regression analysis revealed that CD14(++)CD16(+) monocyte counts were independently associated with VH-TCFA (odds ratio = 1.029, p = 0.004). Furthermore, CD14(++)CD16(+) monocyte counts were significantly correlated with the MAGE score in the non-DM patients (r = 0.544, p = 0.005). CONCLUSIONS: CD14(++)CD16(+) monocyte levels are associated with coronary plaque vulnerability and can serve as a biomarker for VH-TCFA in patients with CAD undergoing lipid-lowering therapy. In patients without DM, glucose fluctuations may alter the balance of monocyte subsets. Trial registration UMIN Registry number: UMIN000021228 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12933-017-0577-8) contains supplementary material, which is available to authorized users. BioMed Central 2017-08-08 /pmc/articles/PMC5549371/ /pubmed/28789689 http://dx.doi.org/10.1186/s12933-017-0577-8 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Original Investigation
Yoshida, Naofumi
Yamamoto, Hiroyuki
Shinke, Toshiro
Otake, Hiromasa
Kuroda, Masaru
Terashita, Daisuke
Takahashi, Hachidai
Sakaguchi, Kazuhiko
Hirota, Yushi
Emoto, Takuo
Amin, Hilman Zulkifli
Mizoguchi, Taiji
Hayashi, Tomohiro
Sasaki, Naoto
Yamashita, Tomoya
Ogawa, Wataru
Hirata, Ken-ichi
Impact of CD14(++)CD16(+) monocytes on plaque vulnerability in diabetic and non-diabetic patients with asymptomatic coronary artery disease: a cross-sectional study
title Impact of CD14(++)CD16(+) monocytes on plaque vulnerability in diabetic and non-diabetic patients with asymptomatic coronary artery disease: a cross-sectional study
title_full Impact of CD14(++)CD16(+) monocytes on plaque vulnerability in diabetic and non-diabetic patients with asymptomatic coronary artery disease: a cross-sectional study
title_fullStr Impact of CD14(++)CD16(+) monocytes on plaque vulnerability in diabetic and non-diabetic patients with asymptomatic coronary artery disease: a cross-sectional study
title_full_unstemmed Impact of CD14(++)CD16(+) monocytes on plaque vulnerability in diabetic and non-diabetic patients with asymptomatic coronary artery disease: a cross-sectional study
title_short Impact of CD14(++)CD16(+) monocytes on plaque vulnerability in diabetic and non-diabetic patients with asymptomatic coronary artery disease: a cross-sectional study
title_sort impact of cd14(++)cd16(+) monocytes on plaque vulnerability in diabetic and non-diabetic patients with asymptomatic coronary artery disease: a cross-sectional study
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549371/
https://www.ncbi.nlm.nih.gov/pubmed/28789689
http://dx.doi.org/10.1186/s12933-017-0577-8
work_keys_str_mv AT yoshidanaofumi impactofcd14cd16monocytesonplaquevulnerabilityindiabeticandnondiabeticpatientswithasymptomaticcoronaryarterydiseaseacrosssectionalstudy
AT yamamotohiroyuki impactofcd14cd16monocytesonplaquevulnerabilityindiabeticandnondiabeticpatientswithasymptomaticcoronaryarterydiseaseacrosssectionalstudy
AT shinketoshiro impactofcd14cd16monocytesonplaquevulnerabilityindiabeticandnondiabeticpatientswithasymptomaticcoronaryarterydiseaseacrosssectionalstudy
AT otakehiromasa impactofcd14cd16monocytesonplaquevulnerabilityindiabeticandnondiabeticpatientswithasymptomaticcoronaryarterydiseaseacrosssectionalstudy
AT kurodamasaru impactofcd14cd16monocytesonplaquevulnerabilityindiabeticandnondiabeticpatientswithasymptomaticcoronaryarterydiseaseacrosssectionalstudy
AT terashitadaisuke impactofcd14cd16monocytesonplaquevulnerabilityindiabeticandnondiabeticpatientswithasymptomaticcoronaryarterydiseaseacrosssectionalstudy
AT takahashihachidai impactofcd14cd16monocytesonplaquevulnerabilityindiabeticandnondiabeticpatientswithasymptomaticcoronaryarterydiseaseacrosssectionalstudy
AT sakaguchikazuhiko impactofcd14cd16monocytesonplaquevulnerabilityindiabeticandnondiabeticpatientswithasymptomaticcoronaryarterydiseaseacrosssectionalstudy
AT hirotayushi impactofcd14cd16monocytesonplaquevulnerabilityindiabeticandnondiabeticpatientswithasymptomaticcoronaryarterydiseaseacrosssectionalstudy
AT emototakuo impactofcd14cd16monocytesonplaquevulnerabilityindiabeticandnondiabeticpatientswithasymptomaticcoronaryarterydiseaseacrosssectionalstudy
AT aminhilmanzulkifli impactofcd14cd16monocytesonplaquevulnerabilityindiabeticandnondiabeticpatientswithasymptomaticcoronaryarterydiseaseacrosssectionalstudy
AT mizoguchitaiji impactofcd14cd16monocytesonplaquevulnerabilityindiabeticandnondiabeticpatientswithasymptomaticcoronaryarterydiseaseacrosssectionalstudy
AT hayashitomohiro impactofcd14cd16monocytesonplaquevulnerabilityindiabeticandnondiabeticpatientswithasymptomaticcoronaryarterydiseaseacrosssectionalstudy
AT sasakinaoto impactofcd14cd16monocytesonplaquevulnerabilityindiabeticandnondiabeticpatientswithasymptomaticcoronaryarterydiseaseacrosssectionalstudy
AT yamashitatomoya impactofcd14cd16monocytesonplaquevulnerabilityindiabeticandnondiabeticpatientswithasymptomaticcoronaryarterydiseaseacrosssectionalstudy
AT ogawawataru impactofcd14cd16monocytesonplaquevulnerabilityindiabeticandnondiabeticpatientswithasymptomaticcoronaryarterydiseaseacrosssectionalstudy
AT hiratakenichi impactofcd14cd16monocytesonplaquevulnerabilityindiabeticandnondiabeticpatientswithasymptomaticcoronaryarterydiseaseacrosssectionalstudy